Evidence map›Paper›PMID 22806328›Full record

ArticleArthritis and rheumatism2012

The molecular basis of skeletal muscle weakness in a mouse model of inflammatory myopathy.

William Coley, Sree Rayavarapu, Gouri S Pandey, Richard L Sabina, Jack H Van der Meulen, Beryl Ampong, Robert L Wortmann, Rashmi Rawat, Kanneboyina Nagaraju

Open access · greenAbstract read
In one paragraph

Article in Arthritis and rheumatism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Skeletal muscle disorders as risk factors for type 2 diabetes.Molecular and cellular endocrinology · 2025
    Review
  3. A window into intracellular events in myositis through subcellular proteomics.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Skeletal muscle: A review of molecular structure and function, in health and disease.Wiley interdisciplinary reviews. Systems biology and medicine · 2020
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

William ColeyChildren's National Medical Center, Washington, DC, USA.
Sree Rayavarapu
Gouri S Pandey
Richard L Sabina
Jack H Van der Meulen
Beryl Ampong
Robert L Wortmann
Rashmi Rawat
Kanneboyina Nagaraju
Children's National · USGeorge Washington University · USDartmouth–Hitchcock Medical Center · USOakland University · US

Funding

Pathogenesis of autoimmune myositis: Role of MHC Class 1R01AR050478 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI NAGARAJU, KANNEBOYINA · 2005 to 2009
$1.9M
Preclinical drug trial in mouse models of inflammationK26OD011171 · OD · STATE UNIVERSITY OF NY,BINGHAMTON · PI NAGARAJU, KANNEBOYINA · 2012 to 2015
$420k
Preclinical drug trial in mouse models of inflammationK26RR032082 · NCRR · CHILDREN'S RESEARCH INSTITUTE · PI NAGARAJU, KANNEBOYINA · 2011 to 2011
$106k
NCRR NIH HHS K26 RR032082NCRR NIH HHS K26-RR-032082NIAMS NIH HHS R01 AR050478NIAMS NIH HHS R01-AR-050478NIH HHS K26 OD011171
6 · The paper itself

Abstract

objectiveIt is generally believed that muscle weakness in patients with polymyositis and dermatomyositis is due to autoimmune and inflammatory processes. However, it has been observed that there is a poor correlation between the suppression of inflammation and a recovery of muscle function in these patients. This study was undertaken to examine whether nonimmune mechanisms also contribute to muscle weakness. In particular, it has been suggested that an acquired deficiency of AMP deaminase 1 (AMPD1) may be responsible for muscle weakness in myositis.

methodsWe performed comprehensive functional, behavioral, histologic, molecular, enzymatic, and metabolic assessments before and after the onset of inflammation in a class I major histocompatibility complex (MHC)-transgenic mouse model of autoimmune inflammatory myositis.

resultsMuscle weakness and metabolic disturbances were detectable in the mice prior to the appearance of infiltrating mononuclear cells. Force contraction analysis of muscle function revealed that weakness was correlated with AMPD1 expression and was myositis specific. Decreasing AMPD1 expression resulted in decreased muscle strength in healthy mice. Fiber typing suggested that fast-twitch muscles were converted to slow-twitch muscles as myositis progressed, and microarray results indicated that AMPD1 and other purine nucleotide pathway genes were suppressed, along with genes essential to glycolysis.

conclusionThese data suggest that an AMPD1 deficiency is acquired prior to overt muscle inflammation and is responsible, at least in part, for the muscle weakness that occurs in the mouse model of myositis. AMPD1 is therefore a potential therapeutic target in myositis.

Indexed as

AMP DeaminaseAnimalsDisease Models, AnimalGene Expression RegulationGlycolysisLeukocytes, MononuclearMiceMice, TransgenicMorpholinosMotor ActivityMuscle ContractionMuscle Fibers, Fast-TwitchMuscle Fibers, Slow-TwitchMuscle, SkeletalMuscle WeaknessMyositisAMPD1 protein, mouseAMP DeaminaseMorpholinos

Identifiers

PMID22806328
PMCPMC3485437
OpenAlexW1988375990

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.